| Literature DB >> 31217619 |
A Silvanto1, T Balamurugan1, I N Bagwan1.
Abstract
BACKGROUND: Adenocarcinoma involving the pancreas shows differences in prognostic parameters including resection margin status depending on subtype. AIM: To assess the reported incidence of each type and the rate of R1 resection using detailed histopathological examination protocol.Entities:
Keywords: Adenocarcinoma; Resection margin
Mesh:
Year: 2019 PMID: 31217619 PMCID: PMC8138538 DOI: 10.32074/1591-951X-41-17
Source DB: PubMed Journal: Pathologica ISSN: 0031-2983
Fig. 1.A) Macroscopic photograph of a pancreaticoduodenectomy specimen demonstrating standardised inking protocol, including application of ink into common bile duct. B) Serial axial section demonstrating yellow ink within intrapancreatic distal common bile duct and firm irregular white tumour in the adjacent pancreas. C) An axial section of pancreas showing an intraductal solid tumour within the main pancreatic duct (marked by arrow). D) An axial section revealing an ampullary tumour (marked by arrow). E) Macroscopic photograph of a pancreaticoduodenectomy demonstrating serial axial slicing and revealing a circumferential firm white tumour within the distal common bile duct with yellow ink (marked by arrow).
Histological diagnosis in 95 pancreatic resections.
| Diagnosis | Number of cases (n = 95) |
|---|---|
| Adenocarcinoma | 58 |
| Non-invasive IPMN | 9 |
| Chronic pancreatitis, stones | 9 |
| Tubular or tubulovillous adenoma of duodenum | 8 |
| Autoimmune pancreatitis | 3 |
| Gangliocytic paraganglioma | 2 |
| Neuroendocrine tumour (one pancreatic, one duodenal) | 2 |
| Pseudocyst | 1 |
| Solid pseudopapillary neoplasm | 1 |
| Microcystic cystadenoma | 1 |
| Common bile duct dysplasia | 1 |
Histopathological findings according to tumour site of origin.
| Tumour origin | Ampullary | Distal CBD | Pancreatic Ductal | IPMN | Duodenal |
|---|---|---|---|---|---|
| Number (n = 58) | 7 (12.1%) | 4 (6.9%) | 23 (39.6%) | 16 (27.6%) | 8 (13.8%) |
| Grade | G2 = 1 | G2 = 1 | G2 = 8 | G2 = 4 | G1 = 1 |
| Average size (mm) | 13 | 15.75 | 26.0 | 27.7 | 27.9 |
| R1 | 1/7 | 3/4 | 16/23 | 10/16 | 0 |
| Involved | Post = 1 | Post = 2 | SMV = 11 | SMV = 7 | 0 |
| pT | pT1 = 2 | pT2 = 1 | pT3 = 23 | pT1 = 1 | pT1 = 2 |
| pN (metastatic nodes) | 5/7 | 4/4 | 19/23 | 11/16 | 5/8 |
| Node ratio | 0.14 | 0.11 | 0.19 | 0.18 | 0.15 |
| LVI | 4/7 | 4/4 | 20/23 | 13/16 | 4/8 |
| PNI | 0/7 | 4/4 | 23/23 | 16/16 | 3/8 |
(Post = posterior, CRM = ductal cirumferential resection margin, SMV = superior mesenteric vein groove resection margin, ant = anterior resection margin, PTM = pancreatic transaction margin, LVI = lymphovascular invasion, PNI = perineural invasion).
Standardised protocol for histopathological assessment of pancreatic resection specimens.
| 1. Examine and measure the size of different organs included in the specimen, for eg: duodenum, pancreas, distal stomach, gall bladder and common bile duct. |
| 2. Open the duodenum and assess the ampulla and duodenum for tumours, polyps or ulcer. |
| 3. Using the standardised protocol ink the specimen as:
anterior pancreatic surface: green posterior pancreatic margin: black superior mesenteric groove (SMV) margin: blue pancreatic transaction margin: red open the common bile duct/common hepatic duct and pass yellow ink through it using a probe. |
| 4. The duodenal, common hepatic duct and the pancreatic transaction margins are submitted. |
| 5. Following inking, the specimen is sliced in the axial plane into transverse sections from proximal to distal. The slices should include all of the inked resection margins and serosal surface. |
| 6. The site of the tumour should be identified in the slices (either pancreatic duct/ head, distal common bile duct- intrapancreatic/ extrapancreatic, ampulla or duodenum) and 2-3 megablocks should be submitted along with a few small blocks of tumour. |
| 7. All the fat around pancreas should be submitted for lymph nodes and the lymph nodes are grouped as anterior and superior pancreaticoduodenal lymph nodes, posterior and inferior pancreaticoduodenal lymph nodes including the superior mesenteric group and the common hepatic/common bile duct lymph nodes. Perigastric lymph nodes if present should be submitted separately. |
| 8. Gall bladder, if present, should be sampled accordingly. |